Moscow State University 'M. V. Lomonosov' is a public research university located in Moscow, Russia. It was founded in 1755 by Mikhail Lomonosov, after whom it was renamed 'Lomonosov University' in 1940. Its current rector is Viktor Sadovnichiy.

During the past decade, Moscow State University n.a. M.V. Lomonosov conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Moscow State University n.a. M.V. Lomonosov" #1 collaborator was "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Chemical Diversity Research Institute" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "King's College London" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Moscow State University n.a. M.V. Lomonosov" are "Acute Kidney Injury" (1 trials), "COVID-19" (1 trials), "Chronic Heart Failure With Preserved Ejection Fraction" (1 trials), "Chronic Kidney Disease" (1 trials) and "Dental Caries in Children" (1 trials). Many other conditions were trialed in "Moscow State University n.a. M.V. Lomonosov" in a lesser frequency.

Most popular intervention types in "Moscow State University n.a. M.V. Lomonosov" are "Drug" (4 trials), "Combination Product" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy" (1 trials), "Favipiravir" (1 trials), "Finerenone (BAY94-8862)" (1 trials) and "Finerenone (Kerendia, BAY94-8862)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Moscow State University n.a. M.V. Lomonosov" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Moscow State University n.a. M.V. Lomonosov". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Moscow State University n.a. M.V. Lomonosov, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Moscow State University n.a. M.V. Lomonosov, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".